Cyanobacteria distribution and abundance in the Spanish water reservoirs during thermal stratification

A study of the distribution and abundance of Cyanobacteria in 47 Spanish water reservoirs revealed a significant correlation between these algae and total phosphorus in the water. Cyanobacteria distribution was related to the N:P ratio, and they were scarce when the atomic ratio of total inorganic N / total P exceeded 50. The N:P ratio was influenced by the geology of the catchment, and it was lower in the solute-poor waters of western Iberian Peninsula, where Cyanobacteria were more abundant (mainly the Nostocales). Therefore, this area would be more prone to present problems derived from Cyanobacteria proliferation than the eastern part of Spain. In the studied reservoirs we have recorded 45 taxa of Cyanobacteria, many of which can produce toxins. A comparison of our results with those of previous studies served to conclude that Cyanobacteria have increased both in biomass and species number in Spanish reservoirs.El estudio de la distribución y abundancia de Cianobacterias en 47 embalses españoles reveló una correlación significativa entre estas algas y la concentración de fósforo total en el agua. La distribución de Cianobacterias estuvo relacionada con el cociente N:P, siendo generalmente poco abundantes cuando la relación atómica N inorgánico total / P total fue superior a 50. La relación N:P en el agua está influenciada por la geología de la cuenca, y fue menor en las aguas menos mineralizadas del oeste de la Península Ibérica, donde las cianobacterias fueron más abundantes (especialmente las nostocales). Por lo tanto, esta zona de la península Ibérica sería más propensa a sufrir problemas relacionados con la proliferación de Cianobacterias que la zona este de España. En los embalses estudiados hemos encontrado 45 taxones de Cianobacterias, muchas de las cuales pueden producir toxinas. La comparación de nuestros resultados con estudios realizados previamente sirvió para concluir que en los embalses españoles se ha producido un aumento del número de especies y de la biomasa de Cianobacterias

California, a new genus of geraniaceae endemic to the southwest of North America

Los datos morfológicos permiten distinguir, a nivel de genero, Erodium macrophyllum Hook. & Am. de las especies incluidas en Erodium y Monsonia (Geraniaceae). Tambien los datos obtenidos de la secuencia de ADN cloroplSstico (»mL-F) apoyan estas diferencias. Por lo tanto, proponemos un nuevo genero monotípico, California Aldas., C. Navarro, P. Vargas, Ll. Saez & Aedo, para que queden mejor reflejadas las relaciones filogeneticas en la clasificacidn de las Geraniaceae. Incluimos una diagnosis, ilustraciones, a diferenciales y una clave de géneros de Geraniaceae. Se propone una nueva combinaci6n: California macrophylla (Hook. & Am.) Aldas., C. Navarro, P. Vargas, Ll. SSez & Aedo, comb, nov. [basion.: Erodium macrophyllum Hook. & Am.]; y se designan dos lectdtiposMorphological data provide evidence for the separation of Erodium macrophyllum Hook. & Arn. in a new genus, different from either Erodium and Monsonia (Geraniaceae). Also cpDNA sequence data (rrnL-F) support this view. Thus, we propose the recognition of a new monotypic genus, California Aldas., C. Navarro, P. Vargas, Ll. Saez & Aedo, to better reflect phylogenetic relationships in Geraniaceae. We provide diagnosis, illustrations, comparative analysis of distinctive characters, and a key to genera of Geraniaceae. The new combinationb proposed is: California macrophylla (Hook. & Am.) Aldas., C. Navarro, P. Vargas, Ll. Saez & Aedo, comb. nov. [basion.: Erodium macrophyllum Hook. & Am.]; and two lectotypes are designe

Function of Glia in Aging and the Brain Diseases.

Microglia cells during aging, neurodegeneration and neuroinflammation show different morphological and transcriptional profiles (related to axonal direction and cell adhesion). Furthermore, expressions of the receptors on the surface and actin formation compared to young are also different. This review delves into the role of glia during aging and the development of the diseases. The susceptibility of different regions of the brain to disease are linked to the overstimulation of signals related to the immune system during aging, as well as the damaging impact of these cascades on the functionality of different populations of microglia present in each region of the brain. Furthermore, a decrease in microglial phagocytosis has been related to many diseases and also has been detected during aging. In this paper we also describe the role of glia in different illness, such as AD, ALS, pain related disorders, cancer, developmental disorders and the problems produced by opening of the blood brain barrier. Future studies will clarify many points planted by this review

Action of low doses of Aspirin in Inflammation and Oxidative Stress induced by aβ1-42 on Astrocytes in primary culture

Aspirin has been used as anti-inflammatory and anti-aggregate for decades but the precise mechanism(s) of action after the presence of the toxic peptide Aβ1-42 in cultured astrocytes remains poorly resolved. Here we use low-doses of aspirin (10-7 M) in astrocytes in primary culture in presence or absence of Aβ1-42 toxic peptide. We noted an increase of cell viability and proliferation with or without Aβ1-42 peptide presence in aspirin treated cells. In addition, a decrease in apoptosis, determined by Caspase 3 activity and the expression of Cyt c and Smac/Diablo, were detected. Also, aspirin diminished necrosis process (LDH levels), pro-inflammatory mediators (IL-β and TNF-α) and NF-ᴋB protein expression, increasing anti-inflammatory PPAR-γ protein expression, preventing Aβ1-42 toxic effects. Aspirin inhibited COX-2 and iNOS without changes in COX-1 expression, increasing anti-oxidant protein (Cu/Zn-SOD and Mn-SOD) expression in presence or absence of Aβ1-42. Taken together, our results show that aspirin, at low doses increases cell viability by decreasing inflammation and oxidative stress, preventing the deleterious effects of the Aβ1-42 peptide on astrocytes in primary culture. The use of low doses of aspirin may be more suitable for Alzheimer's disease

Facilitation of Insulin Effects by Ranolazine in Astrocytes in Primary Culture

Ranolazine (Rn) is a drug used to treat persistent chronic coronary ischemia. It has also been shown to have therapeutic benefits on the central nervous system and an anti-diabetic effect by lowering blood glucose levels; however, no effects of Rn on cellular sensitivity to insulin (Ins) have been demonstrated yet. The present study aimed to investigate the permissive effects of Rn on the actions of Ins in astrocytes in primary culture. Ins (10−8 M), Rn (10−6 M), and Ins + Rn (10−8 M and 10−6 M, respectively) were added to astrocytes for 24 h. In comparison to control cells, Rn and/or Ins caused modifications in cell viability and proliferation. Rn increased protein expression of Cu/Zn-SOD and the pro-inflammatory protein COX-2 was upregulated by Ins. On the contrary, no significant changes were found in the protein expression of NF-κB and IκB. The presence of Rn produced an increase in p-ERK protein and a significant decrease in COX-2 protein expression. Furthermore, Rn significantly increased the effects of Ins on the expression of p-AKT, p-eNOS, p-ERK, Mn-SOD, and PPAR-γ. In addition, Rn + Ins produced a significant decrease in COX-2 expression. In conclusion, Rn facilitated the effects of insulin on the p-AKT, p-eNOS, p-ERK, Mn-SOD, and PPAR-γ signaling pathways, as well as on the anti-inflammatory and antioxidant effects of the hormone

Arginine Vasopressin Enhances Sympathetic Constriction Through the V1 Vasopressin Receptor in Human Saphenous Vein

Background—Arginine vasopressin (AVP) not only acts directly on blood vessels through V1 receptor stimulation but also may modulate adrenergic-mediated responses in animal experiments in vivo and in vitro. The aim of the present study was to investigate whether AVP can contribute to an abnormal adrenergic constrictor response of human saphenous veins. Methods and Results—Saphenous vein rings were obtained from 32 patients undergoing coronary artery bypass surgery. The vein rings were suspended in organ bath chambers for isometric recording of tension. AVP (331029 mol/L) enhanced the contractions elicited by electrical field stimulation at 1, 2, and 4 Hz (by 80%, 70%, and 60%, respectively) and produced a leftward shift of the concentration-response curve to norepinephrine (half-maximal effective concentration decreased from 6.8731027 to 1.0431027 mol/L; P,.05). The V1 vasopressin receptor antagonist d(CH2)5Tyr(Me)AVP (1026 mol/L) prevented the potentiation evoked by AVP. The selective V1 receptor agonist [Phe,2 Orn8]-vasotocin (331029 mol/L) induced potentiation of electrical stimulation– evoked responses, which was also inhibited in the presence of the V1 receptor antagonist (1026 mol/L). In contrast, the V2 receptor agonist desmopressin (1029 to 1027 mol/L) did not modify neurogenic responses, and the V2 receptor antagonist [d(CH2)5, D-Ile,2 Ile,4 Arg8]-vasopressin (1028 to 1026 mol/L) did not prevent the potentiation induced by AVP. The dihydropyridine calcium antagonist nifedipine (1026 mol/L) did not affect the potentiating effect of AVP. Conclusions—The results suggest that low concentrations of AVP facilitate sympathetic neurotransmission and potentiate constrictor effects of norepinephrine in human saphenous veins. These effects appear to be mediated by V1 receptor stimulation and are independent of calcium entry through dihydropyridine calcium channels. Thus, AVP may contribute to vascular mechanisms involved in acute ischemic syndromes associated with venous grafts, particularly if the sympathetic nervous system is activated. (Circulation. 1998;97:865-870.)Medina Besso, Pascual, [email protected] ; Acuña Torre, Antonio, [email protected] ; Martinez Leon, Juan Baustista, [email protected] ; Vila Salinas, José M, [email protected] ; Aldasoro Celaya, Martin, [email protected] ; Lluch Lopez, Salvador, [email protected]

Contractile responses of human thyroid arteries to vasopressin

Aims: In the present study we investigated the intervention of nitric oxide and prostacyclin in the responses to vasopressin of isolated thyroid arteries obtained from multi-organ donors. Main methods: Paired artery rings from glandular branches of the superior thyroid artery, one normal and the other deendothelised, were mounted in organ baths for isometric recording of tension. Concentration-response curves to vasopressin were determined in the absence and in the presence of either the vasopressin V1 receptor antagonist d(CH2)5Tyr(Me)AVP (10−8 M), the nitric oxide synthase inhibitor NG-monomethyl-Larginine (L-NMMA, 10−4 M), or the inhibitor of prostaglandins indomethacin (10−6 M). Key findings: In artery rings under resting tension, vasopressin produced concentration-dependent, endotheliumindependent contractions. The vasopressin V1 receptor antagonist d(CH2)5Tyr(Me)AVP (10−8 M) displaced the control curve to vasopressin 19-fold to the right in a parallelmanner. The contractile response to vasopressinwas unaffected by L-NMMA or by indomethacin. Significance: Vasopressin causes constriction of human thyroid arteries by stimulation of V1 vasopressin receptors located on smooth muscle cells. These effects are not linked to the presence of an intact endothelium or to the release of nitric oxide or prostaglandins. The constriction of thyroid arteries may be particularly relevant in certain pathophysiological circumstances in which vasopressin is released in amounts that could interfere with the blood supply to the thyroid gland

Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice.

Tocilizumab (TCZ) has shown efficacy in clinical trials on giant cell arteritis (GCA). Real-world data are scarce. Our objective was to assess efficacy and safety of TCZ in unselected patients with GCA in clinical practice Methods: Observational, open-label multicenter study from 40 national referral centers of GCA patients treated with TCZ due to inefficacy or adverse events of previous therapy. Outcomes variables were improvement of clinical features, acute phase reactants, glucocorticoid-sparing effect, prolonged remission and relapses. A comparative study was performed: (a) TCZ route (SC vs. IV); (b) GCA duration (≤6 vs. >6 months); (c) serious infections (with or without); (d) ≤15 vs. >15 mg/day at TCZ onset. 134 patients; mean age, 73.0 ± 8.8 years. TCZ was started after a median [IQR] time from GCA diagnosis of 13.5 [5.0-33.5] months. Ninety-eight (73.1%) patients had received immunosuppressive agents. After 1 month of TCZ 93.9% experienced clinical improvement. Reduction of CRP from 1.7 [0.4-3.2] to 0.11 [0.05-0.5] mg/dL (p  In clinical practice, TCZ yields a rapid and maintained improvement of refractory GCA. Serious infections appear to be higher than in clinical trials